SCHEDULE 13G/A 0001442891 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 06/30/2025 0001566044 VYNE Therapeutics Inc. 92941V308 685 Route 202/206 N Suite 301 Bridgewater NJ 08807 Rule 13d-1(c) Eventide Asset Management, LLC DE 1849597.00 0.00 1849597.00 0.00 1849597.00 N 9.99 IA Finny Kuruvilla, M.D. Ph. D. X1 0.00 1849597.00 0.00 1849597.00 1849597.00 N 9.99 HC IN Robin C. John X1 0.00 1849597.00 0.00 1849597.00 1849597.00 N 9.99 HC IN VYNE Therapeutics Inc. 685 Route 202/206 N., Suite 301, Bridgewater, NJ 08807 (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John") Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110 Eventide: Delaware Kuruvilla: United States John: United States N IA HC (i) Eventide: 1,849,597 (ii) Kuruvilla: 1,849,597 (iii) John: 1,849,597 (i) Eventide: 9.99% (ii) Kuruvilla: 9.99% (iii) John: 9.99% (1) Eventide: 1,849,597 (2) Kuruvilla: 0 (3) John: 0 (1) Eventide: 0 (2) Kuruvilla: 1,849,597 (3) John: 1,849,597 (1) Eventide: 1,849,597 (2) Kuruvilla: 0 (3) John: 0 (1) Eventide: 0 (2) Kuruvilla: 1,849,597 (3) John: 1,849,597 Y N This Schedule 13G amendment is being filed to disclose a change in the mix of security types owned. As of June 30, 2025, Eventide is the beneficial owner of common stock of the Issuer ("Common Stock") issuable upon the exercise of pre-funded warrants (the "Warrants") as the investment adviser to Eventide Healthcare Innovation Fund I LP, a private fund (the "Fund"); provided that the Warrants may not be exercised if such exercise would cause the holder to beneficially own in excess of 9.99% of the number of shares of the Issuer's Common Stock then outstanding. Eventide Asset Management, LLC is the Managing Member of Eventide Healthcare Innovation Fund I GP LLC which is the general partner of the Fund. The Warrants would be exercisable for up to 5,287,413 shares of Common Stock, subject to the limitation on exercise. If not for such limitation on exercise, the Reporting Persons would beneficially own in excess of 9.99% of the Issuer's Common Stock. The percentages reported herein regarding the Reporting Persons' holdings are calculated based upon information in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended on March 31, 2025, as filed with the Securities and Exchange Commission on May 8, 2025, citing 16,664,892 outstanding shares of Common Stock of the Issuer as of May 1, 2025. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities. EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them. Eventide Asset Management, LLC Date: August 14, 2025 By: /s/ Peter J. Luiso Name: Peter J. Luiso Title General Counsel Finny Kuruvilla, M.D., Ph. D. Date: August 14, 2025 By: /s/ Finny Kuruvilla, M.D., Ph. D. Name: Finny Kuruvilla, M.D., Ph. D. Robin C. John Date: August 14, 2025 By: /s/ Robin C. John Name: Robin C. John Eventide Asset Management, LLC /s/ Peter J. Luiso 08/14/2025 Finny Kuruvilla, M.D. Ph. D. /s/ Finny Kuruvilla, M.D., Ph. D. 08/14/2025 Robin C. John /s/ Robin C. John 08/14/2025